Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 13/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.54 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL242978 | 0.91 | CYP19A1 (0.61) | CYP19A1KCNH2TRPV1ALOX12ALOX15 | |
| SCHEMBL4432673 | 0.84 | CYP19A1 (0.56) | CYP19A1KCNH2TRPV1ALOX12ALOX15 | |
| SCHEMBL12052437 | 0.84 | CYP19A1 (0.83) | CYP19A1KCNH2TRPV1ALOX12ALOX15 | |
| SCHEMBL19410272 | 0.81 | CYP19A1 (0.62) | CYP19A1KCNH2TRPV1ALOX12ALOX15 | |
| SCHEMBL19410273 | 0.81 | CYP19A1 (0.55) | CYP19A1KCNH2TRPV1ALOX12ALOX15 | |
| SCHEMBL2070571 | 0.81 | CYP19A1 (0.61) | CYP19A1KCNH2TRPV1ALOX12ALOX15 | |
| SCHEMBL3957591 | 0.80 | ALOX12 (0.53) | CYP19A1KCNH2TRPV1ALOX12ALOX15 | |
| SCHEMBL12055312 | 0.80 | ALOX12 (0.44) | CYP19A1KCNH2TRPV1ALOX12ALOX15 | |
| SCHEMBL2742795 | 0.80 | CYP19A1 (0.63) | CYP19A1KCNH2TRPV1ALOX12ALOX15 | |
| SCHEMBL3956230 | 0.80 | ALOX12 (0.46) | CYP19A1KCNH2TRPV1ALOX12ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160136129-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | NOVOGEN RESEARCH PTY LTD (AU) | 2016-05-19 | — | — | US | disclosed |
| US-9198895-B2 | Chroman derivatives, medicaments and use in therapy | MEI PHARMA, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150238458-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | NOVOGEN RESEARCH PTY LTD (AU) | 2015-08-27 | — | — | US | disclosed |
| US-20150240275-A1 | ENZYME ASSOCIATED WITH EQUOL SYNTHESIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-08-27 | — | — | US | disclosed |
| US-8993296-B2 | Enzyme associated with equol synthesis | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-03-31 | — | — | US | disclosed |
| US-8957109-B2 | Chroman derivatives, medicaments and use in therapy | MEI PHARMA, INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-20140315264-A1 | ENZYME ASSOCIATED WITH EQUOL SYNTHESIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
| US-20140161908-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | MEI PHARMA, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-8669088-B2 | Enzyme associated with equol synthesis | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-03-11 | — | — | US | disclosed |
| US-20130150568-A1 | ENZYME ASSOCIATED WITH EQUOL SYNTHESIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-06-13 | — | — | US | disclosed |
| US-8461361-B2 | Chroman derivatives, medicaments and use in therapy | MARSHALL EDWARDS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-8399232-B2 | Enzyme associated with equol synthesis | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-19 | — | — | US | disclosed |
| US-20120172424-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | MARSHALL EDWARDS, INC. (US) | 2012-07-05 | — | — | US | disclosed |
| US-8163795-B2 | Chroman derivatives, medicaments and use in therapy | MARSHALL EDWARDS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20120004296-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | MARSHALL EDWARDS, INC (US) | 2012-01-05 | — | — | US | disclosed |
| US-20100330627-A1 | ENZYME ASSOCIATED WITH EQUOL SYNTHESIS | OTSUKA PHARMACEUTICAL CO. LTD. (JP) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150238458-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | CDYL, XPA, TP53 | CYP19A1 2946/4885KCNH2 4760/4885TRPV1 3783/4885 |
| US-20160136129-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | CDYL, XPA, TP53 | CYP19A1 2946/4885KCNH2 4760/4885TRPV1 3783/4885 |
| US-20120172424-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | CDYL, XPA, TP53 | CYP19A1 2946/4885KCNH2 4760/4885TRPV1 3783/4885 |
| US-20100330627-A1 | ENZYME ASSOCIATED WITH EQUOL SYNTHESIS | DHODH, DHPS, HPGD | CYP19A1 31/4885KCNH2 4149/4885TRPV1 924/4885 |
| US-20140161908-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | CDYL, XPA, TP53 | CYP19A1 1936/4885KCNH2 4711/4885TRPV1 3181/4885 |
| US-20120004296-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | CDYL, XPA, TP53 | CYP19A1 2946/4885KCNH2 4760/4885TRPV1 3783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.